|
9-THC
and
9-THCA
Cannabinoids
Aphios
manufactures natural pharmaceutical grade 9-THC
( 9-tetrahydrocannabinol)
and its precursor 9-THCA
( 9-tetrahydrocannabinolic
acid) utilizing its patented SuperFluids™
CXP process [US Patent No. 5,750,709].
These natural cannabinoid products, directly isolated from
the plant Cannabis sativa, are being developed for
treating pain in cancer patients, cachexia or wasting in AIDS
patients, nausea and emesis, and relief to Alzheimer’s
patients while increasing their appetite.
A
select number of the 65 cannabinoids, the medically active
components of Cannabis, hold the promise of providing new
drugs for a variety of treatment purposes, including 9-THC.
The use of marijuana (Cannabis) for medical treatments
has the legal disadvantage that distribution of the plant
material to patients violates US Federal law. Smoking Cannabis
has the medical disadvantage that the smoke contains many
toxic components in common with tobacco smoke, and delivers
a highly variable dose of 9-THC
and other cannabinoids.
While 9-THC
can be synthesized, the process is complex and expensive.
Synthetic 9-THC
(dronabinol) used to be manufactured by only one company in
the United States, Norac, Azusa, CA, which has an exclusive
supply agreement with Unimed for use in its Marinol® product,
a preparation of synthetic dronabinol dissolved in sesame
oil. Marinol® is approved by the US FDA as an appetite
stimulant for HIV/AIDS patients and as an anti-emetic to stem
the nausea and vomiting associated with cancer chemotherapy.
Oral administration of Marinol® causes slow, variable
9-THC
uptake, while the oil-based capsule can be difficult to digest,
especially in patients suffering nausea from chemotherapy.
Dronabinol, now generic, is manufactured by several companies
including AMRI Rensselaer, Inc., Rhodes Technologies, Mallinckrodt,
Inc., and Austin Pharma, LLC.
Our
engineers and scientists have developed a cost-effective process
to rapidly manufacture pharmaceutical-grade 9-THC
and and 9-THCA
cannabinoid fractions by utilizing Aphios’ patented
SuperFluids™ CXF and CXP technologies. 9-THCA
is more stable than 9-THC
but not active. This acid precursor stoichometrically converts
to 9-THC
when heated to 100°C or higher. 9-THCA
is thus an ideal prodrug for enhanced drug delivery devices.
Aphios is seeking collaborative partners to: (1) develop an
orally available natural 9-THC
for cancer pain and AIDS cachexia; and (2) develop 9-THCA
as a pro-drug for cancer, AIDS and Alzheimer’s patients.
Home
l Company | Infectious
Diseases | Oncology | Nutraceuticals
| Product Pipeline | Purchase
Products | Technology Platforms
| Equipment |Patents
| Press
Releases | Contact Aphios
©1999-
2009 Aphios® Corporation
All rights reserved
|